Related Experiment Video
Updated: Aug 24, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
HCV and HIV: a tale of two viruses
1Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Insights
HIV patients with hepatitis C virus (HCV) coinfection face accelerated liver disease. While combination therapy shows promise, sustained virologic response rates remain lower than in HCV monoinfection.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Liver disease is a significant cause of illness and death in human immunodeficiency virus (HIV)-infected individuals.
- Hepatitis C virus (HCV) coinfection exacerbates liver damage, fibrosis, cirrhosis, and liver failure.
- Hepatitis B virus and drug toxicity are additional contributing factors to liver injury in HIV patients.
Purpose of the Study:
- To evaluate the efficacy of peginterferon with ribavirin for treating HCV in coinfected HIV patients.
- To compare treatment outcomes in coinfected subjects versus those with HCV monoinfection.
Main Methods:
- Analysis of three major randomized clinical trials.
- Assessment of peginterferon plus ribavirin treatment regimens.
- Comparison of sustained virologic response rates.
Main Results:
- Peginterferon with ribavirin demonstrated improved efficacy for HCV treatment in coinfected patients compared to HCV monoinfected patients.
- However, response rates were lower in the coinfected group.
- Sustained virologic response rates ranged from 27% to 40%.
Conclusions:
- Combination therapy offers benefits for HCV treatment in HIV-coinfected individuals.
- Further research is needed to optimize treatment strategies and improve outcomes.
- HCV coinfection presents unique challenges in managing liver disease within the HIV population.
Abstract:
Liver disease has emerged as a major cause of morbidity and mortality in patients infected with the human immunodeficiency virus. Hepatic injury is highly associated with hepatitis C virus (HCV) infection, though hepatitis B virus and drug-induced hepatotoxicity are also important cofactors. HCV coinfection is linked to increased hepatic fibrosis progression, leading to development of cirrhosis and liver failure earlier than in HCV monoinfected patients. Initiation of highly active antiretroviral treatment regimens may paradoxically increase HCV loads. Some data suggest that HCV coinfection may hasten progression of AIDS, but this remains controversial. Three major randomized clinical trials demonstrate improved efficacy of peginterferon with ribavirin for treatment of HCV in coinfected subjects compared to those with HCV alone. However, response rates are lower than those observed in patients with HCV monoinfection. Sustained virologic response rates of 27% to 40% are reported.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Viral Recombination
Viruses with RNA Genomes
